- Home
- SPOK vs FENC Comparison
SPOK vs FENC Comparison
Compare SPOK & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPOK | FENC |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | 415 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 230.8M |
| IPO Year | 2004 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SPOK | FENC |
|---|---|---|
| Price | $10.98 | $9.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $14.00 | ★ $14.50 |
| AVG Volume (30 Days) | 155.0K | ★ 244.6K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ 2.74 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $139,708,000.00 | $44,642,000.00 |
| Revenue This Year | $1.70 | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | $122.11 | ★ N/A |
| Revenue Growth | ★ 1.49 | N/A |
| 52 Week Low | $9.95 | $5.65 |
| 52 Week High | $19.31 | $10.27 |
Technical Indicators
Market Signals| Indicator | SPOK | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 76.35 |
| Support Level | $10.87 | $7.45 |
| Resistance Level | $11.55 | $9.92 |
| Average True Range (ATR) | 0.35 | 0.61 |
| MACD | 0.04 | 0.36 |
| Stochastic Oscillator | 85.17 | 86.60 |
Price Performance
Historical ComparisonAbout SPOK Spok Holdings Inc.
Spok Holdings Inc is a provider of healthcare communications. The company delivers clinical communication and collaboration solutions to help protect the health, well-being, and safety of people in the United States and abroad, on a limited basis, in Europe, Canada, Australia, Asia, and the Middle East. The company develops, sells, and supports enterprise-wide systems principally for healthcare and other organizations needing to automate, centralize, and standardize their approach to clinical and critical communications. The company offers its services and products to three market segments: healthcare, government, and large enterprise, with a greater emphasis on the healthcare market segment. Geographically, the company generates the majority of its revenue from the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.